- Home
- KRRO vs FATE Comparison
KRRO vs FATE Comparison
Compare KRRO & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRRO
- FATE
- Stock Information
- Founded
- KRRO 2014
- FATE 2007
- Country
- KRRO United States
- FATE United States
- Employees
- KRRO N/A
- FATE N/A
- Industry
- KRRO Biotechnology: Pharmaceutical Preparations
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KRRO Health Care
- FATE Health Care
- Exchange
- KRRO Nasdaq
- FATE Nasdaq
- Market Cap
- KRRO 147.4M
- FATE 125.7M
- IPO Year
- KRRO 2019
- FATE 2013
- Fundamental
- Price
- KRRO $20.04
- FATE $1.15
- Analyst Decision
- KRRO Strong Buy
- FATE Hold
- Analyst Count
- KRRO 7
- FATE 7
- Target Price
- KRRO $96.71
- FATE $3.58
- AVG Volume (30 Days)
- KRRO 128.5K
- FATE 1.4M
- Earning Date
- KRRO 08-12-2025
- FATE 08-12-2025
- Dividend Yield
- KRRO N/A
- FATE N/A
- EPS Growth
- KRRO N/A
- FATE N/A
- EPS
- KRRO N/A
- FATE N/A
- Revenue
- KRRO $6,281,000.00
- FATE $8,470,000.00
- Revenue This Year
- KRRO $65.08
- FATE N/A
- Revenue Next Year
- KRRO N/A
- FATE N/A
- P/E Ratio
- KRRO N/A
- FATE N/A
- Revenue Growth
- KRRO N/A
- FATE N/A
- 52 Week Low
- KRRO $10.29
- FATE $0.66
- 52 Week High
- KRRO $98.00
- FATE $4.20
- Technical
- Relative Strength Index (RSI)
- KRRO 64.81
- FATE 53.09
- Support Level
- KRRO $18.52
- FATE $1.06
- Resistance Level
- KRRO $21.08
- FATE $1.18
- Average True Range (ATR)
- KRRO 1.67
- FATE 0.09
- MACD
- KRRO 0.29
- FATE 0.02
- Stochastic Oscillator
- KRRO 78.80
- FATE 72.73
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.